# InnoPac

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innopac

- Industry: Healthcare
- Headquarters: Shanghai, China
- Website: https://www.innopac.com/
- Latest round: Series B (Jan 16, 2026)
- Investors on record: 3

## About

Founded in 2021 and based in Shanghai, China, Shanghai InnoPac Medical Technology Co.,Ltd., trading as InnoPac develops advanced packaging solutions and medical devices to enhance pharmaceutical supply chains. The company has not undergone any strategic pivots, and there is no mention of subsidiaries or parent companies. In January 2026, InnoPac raised Series B+ funding led by new investor GF Xinde Investment, with participation from new investors Tonghua Dongbao Pharmaceutical Co., Ltd., Huatai Zijin Investment and FarmerKey.
InnoPac specializes in developing high-end pharmaceutical packaging materials and medical devices designed for pharmaceutical and medical device companies. Their offerings include innovative packaging solutions that ensure compliance with regulatory standards while addressing challenges such as contamination prevention and shelf-life extension. InnoPac's client base spans Asia, Europe, and North America, serving a diverse range of end users.
The company generates revenue through direct business-to-business transactions with pharmaceutical companies and healthcare institutions. The revenue model is based on sales of proprietary packaging materials and medical devices, with transactions typically involving bulk orders and long-term contracts. The company tailors pricing plans to meet client needs, with flagship products contributing significantly to its revenue stream. Strategic partnerships further enhance its market presence.

## Funding rounds

- Series B, Jan 16, 2026 — GF Xinde Investment, Huatai Zijin Investment, Tonghua Dongbao Pharmaceutical Co., Ltd.

## Investors

- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series B
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series B
- Tonghua Dongbao Pharmaceutical Co., Ltd. — Series B